Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKYANASDAQ:ISONASDAQ:NAUTNASDAQ:SEER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKYAAkoya Biosciences$1.24-1.2%$1.20$0.93▼$3.42$61.60M1.34389,348 shs250,971 shsISOIsoPlexis$0.76$0.86$0.60▼$5.10$30.28M1.3268,375 shsN/ANAUTNautilus Biotechnology$0.73-2.8%$0.77$0.66▼$3.09$91.58M1.41118,594 shs95,486 shsSEERSeer$2.14+11.5%$1.94$1.56▼$2.63$125.98M1.58341,280 shs358,182 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKYAAkoya Biosciences0.00%-1.98%+1.23%-20.32%-42.56%ISOIsoPlexis0.00%0.00%0.00%0.00%0.00%NAUTNautilus Biotechnology0.00%+1.78%+9.99%-39.91%-72.81%SEERSeer0.00%-5.95%-3.66%-4.13%+9.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKYAAkoya Biosciences1.7214 of 5 stars3.01.00.00.03.01.70.6ISOIsoPlexisN/AN/AN/AN/AN/AN/AN/AN/ANAUTNautilus Biotechnology2.6251 of 5 stars3.02.00.00.02.74.20.6SEERSeer1.7384 of 5 stars3.01.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKYAAkoya Biosciences 2.00Hold$2.51102.91% UpsideISOIsoPlexis 0.00N/AN/AN/ANAUTNautilus Biotechnology 2.00Hold$2.42232.87% UpsideSEERSeer 2.00Hold$3.0040.19% UpsideCurrent Analyst Ratings BreakdownLatest ISO, SEER, NAUT, and AKYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.80 ➝ $1.084/29/2025AKYAAkoya BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$3.50 ➝ $1.804/14/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.40 ➝ $1.653/25/2025AKYAAkoya BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$3.50 ➝ $1.803/18/2025AKYAAkoya BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$3.50 ➝ $3.503/5/2025AKYAAkoya BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$2.40(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKYAAkoya Biosciences$79.96M0.77N/AN/A$1.10 per share1.12ISOIsoPlexis$16.76M1.81N/AN/A$1.04 per share0.73NAUTNautilus BiotechnologyN/AN/AN/AN/A$2.12 per shareN/ASEERSeer$15.06M8.36N/AN/A$6.17 per share0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKYAAkoya Biosciences-$63.32M-$0.97N/AN/AN/A-66.77%-162.99%-32.76%8/4/2025 (Estimated)ISOIsoPlexis-$106M-$2.70N/AN/AN/A-632.41%-127.86%-71.41%N/ANAUTNautilus Biotechnology-$63.67M-$0.54N/AN/AN/AN/A-28.85%-24.93%7/29/2025 (Estimated)SEERSeer-$86.28M-$1.41N/AN/AN/A-565.83%-21.96%-19.85%8/14/2025 (Estimated)Latest ISO, SEER, NAUT, and AKYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SEERSeer-$0.37-$0.34+$0.03-$0.34$3.25 million$4.21 million5/12/2025Q1 2025AKYAAkoya Biosciences-$0.29-$0.32-$0.03-$0.32$20.19 million$16.64 million4/29/2025Q1 2025NAUTNautilus Biotechnology-$0.14-$0.13+$0.01-$0.13N/AN/A3/17/2025Q4 2024AKYAAkoya Biosciences-$0.15-$0.17-$0.02-$0.17$21.34 million$21.34 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKYAAkoya BiosciencesN/AN/AN/AN/AN/AISOIsoPlexisN/AN/AN/AN/AN/ANAUTNautilus BiotechnologyN/AN/AN/AN/AN/ASEERSeerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKYAAkoya Biosciences5.622.751.85ISOIsoPlexis1.124.062.50NAUTNautilus BiotechnologyN/A16.6516.65SEERSeerN/A18.3617.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKYAAkoya Biosciences79.42%ISOIsoPlexis44.91%NAUTNautilus Biotechnology50.71%SEERSeer75.20%Insider OwnershipCompanyInsider OwnershipAKYAAkoya Biosciences7.30%ISOIsoPlexis6.40%NAUTNautilus Biotechnology41.10%SEERSeer15.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKYAAkoya Biosciences9049.88 million45.95 millionOptionableISOIsoPlexis45939.76 million37.22 millionNot OptionableNAUTNautilus Biotechnology130126.15 million74.71 millionOptionableSEERSeer16058.87 million50.12 millionOptionableISO, SEER, NAUT, and AKYA HeadlinesRecent News About These CompaniesAbu Dhabi's Al Seer Marine sets up tanker JV, secures $57mln ADCB term loanJune 2 at 2:47 AM | zawya.comProstate Cancer Surgery Rates Drop in Low-Risk CasesJune 1 at 3:04 PM | emjreviews.comDoc-turned-seer of Telugu origin to head Courtallam peethamJune 1 at 3:04 PM | msn.comSeer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea ...June 1 at 9:26 AM | bakersfield.comLearn Kannada and respect other languages: SeerJune 1 at 9:26 AM | starofmysore.comSeer, Inc. and Korea University Launch First Large-Scale Study to Identify Early-Onset Cancer Biomarkers Using Proteograph ONE AssayJune 1 at 7:41 AM | quiverquant.comSeer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young AdultsJune 1 at 7:00 AM | globenewswire.comSeer, Inc. (NASDAQ:SEER) Stake Raised by Two Sigma Advisers LPJune 1 at 3:59 AM | marketbeat.comBulldozers raze illegal ashram of arrested self-styled seerMay 31 at 2:26 AM | thehansindia.comSeer Jagadguru Rambhadracharya seeks PoK as ‘guru dakshina’ from Army chief general Upendra DwivediMay 30 at 9:26 PM | msn.comKarnataka Demolishes 'Illegal' Ram Mandir Mutt After Seer’s ArrestMay 30 at 6:50 AM | msn.comMan Group plc Has $38,000 Stake in Seer, Inc. (NASDAQ:SEER)May 30 at 3:44 AM | marketbeat.com‘Want PoK back as dakshina’: Seer told Army Chief DwivediMay 30 at 1:50 AM | thehansindia.comMutt demolished in Raibag after seer’s arrest in Pocso caseMay 30 at 1:50 AM | timesofindia.indiatimes.comIllegal Ram Mandir in Karnataka's Belagavi demolished after seer held for abduction, rapeMay 30 at 1:50 AM | msn.comAsked for Pakistan-occupied Kashmir as gurudakshina from Army staff chief Dwivedi, says UP seerMay 29, 2025 | deccanherald.comHindu seer Rambhadracharya seeks PoK as Guru Dakshina from Army Chief DwivediMay 29, 2025 | msn.comSeer demands PoK in guru dakshina from Army ChiefMay 29, 2025 | msn.comSeer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and EfficiencyMay 29, 2025 | globenewswire.comYounger Adults See Rising Pancreatic & Colorectal Cancer RatesMay 27, 2025 | targetedonc.comPuri seer’s security to be enhancedMay 25, 2025 | thehansindia.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookHow Does D-Wave Stack Up Against Quantum Competitors?By Nathan Reiff | May 20, 2025View How Does D-Wave Stack Up Against Quantum Competitors?ISO, SEER, NAUT, and AKYA Company DescriptionsAkoya Biosciences NASDAQ:AKYA$1.24 -0.02 (-1.20%) Closing price 03:59 PM EasternExtended Trading$1.22 -0.02 (-1.62%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.IsoPlexis NASDAQ:ISOIsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.Nautilus Biotechnology NASDAQ:NAUT$0.73 -0.02 (-2.81%) Closing price 03:59 PM EasternExtended Trading$0.73 +0.00 (+0.28%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Seer NASDAQ:SEER$2.14 +0.22 (+11.46%) Closing price 03:59 PM EasternExtended Trading$2.14 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
